Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Morphic Holding Inc chart...

About the Company

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Exchange

NASDAQ

$19M

Total Revenue

117

Employees

$2B

Market Capitalization

-10.37

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MORF News

Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

3d ago, source: TMCnet

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of ...

Commit To Buy Morphic Holding At $20, Earn 10.9% Annualized Using Options

13d ago, source: Nasdaq

Investors considering a purchase of Morphic Holding Inc (Symbol: MORF) shares, but tentative about paying the going market price of $34.97/share, might benefit from considering selling puts among ...

Morphic Appoints Simon Cooper As Chief Medical Officer

10d ago, source:

Morphic Holding, Inc. (MORF) on Tuesday announced the appointment of Simon Cooper as the Chief Medical Officer. With a background in ...

Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating

21d ago, source: Business Insider

Morphic Holding (MORF) Company Description: Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics.

Morphic Holding Inc MORF

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

1mon ago, source: Zacks.com on MSN

Morphic Holding, Inc. (MORF) closed the last trading session at $35.30, gaining 16.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

New Strong Buy Stocks for February 14th

1mon ago, source: Zacks.com on MSN

Lumen Technologies, Inc. price-consensus-chart | Lumen Technologies, Inc. Quote Morphic Holding, Inc. MORF: This ...

Morphic Holding (MORF) Earnings Dates & Reports

1mon ago, source: Investing

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Morphic Holding Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...